Capitalizing on new opportunities for stem cell prods

Research and advisory firm BioInformatics has announced the pending release of its newest report, Capitalizing on New Opportunities for  Stem Cell Products. As a result of the USA's March 9, 2009, reversal of  the 2001 restrictions on federal funding of human embryonic stem-cell  research, suppliers of stem cell-related products are in need of a fast,  accurate assessment of new opportunities in this market. In this  report, BioInformatics (http:// www.gene2drug.com) fielded a detailed  60-question survey to scientists worldwide about their current - and  planned - areas of stem-cell research, usage of stem-cell products and  preferred suppliers. The report is scheduled to release at the end of  April, and is available at pre-release pricing until May 17.

Scientists involved in stem-cell research, whether they are more focused  on understanding basic stem-cell biology, developing cell-based  therapies using stem cells, or using stem cells to improve drug target  validation and toxicology screening, rely on stem-cell research  products from major life science suppliers, as well as more niche  stem-cell companies. In this report, scientists specify the percentage  of stem-cell culture products purchased from various suppliers

Life science suppliers can use this study to determine areas poised for  growth (ie, media, sera, supplements and cell lines) in the stem-cell  research products market, identify potential key competitors and plan a  long-term strategy to secure a leading position in this expanding  market. The report includes detailed market share estimates across  major stem-cell product categories by market segment, geographic region  and top suppliers.